1
|
Yasuda K, Maeda H, Kinoshita R, Minayoshi Y, Mizuta Y, Nakamura Y, Imoto S, Nishi K, Yamasaki K, Sakuragi M, Nakamura T, Ikeda-Imafuku M, Iwao Y, Ishima Y, Ishida T, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticles for the Treatment of Hepatitis. ACS NANO 2023; 17:16668-16681. [PMID: 37579503 DOI: 10.1021/acsnano.3c02877] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/16/2023]
Abstract
Hepatitis is an inflammation of the liver caused by the inadequate elimination of reactive oxygen species (ROS) derived from Kupffer cells. Edaravone is clinically used as an antioxidant but shows poor liver distribution. Herein, we report on the design of a Kupffer cell-oriented nanoantioxidant based on a disulfide cross-linked albumin nanoparticle containing encapsulated edaravone (EeNA) as a therapeutic for the treatment of hepatitis. Since the edaravone is bound to albumin, this results in a soluble and stable form of edaravone in water. Exchanging the intramolecular disulfide bonds to intermolecular disulfide bridges of albumin molecules allowed the preparation of a redox responsive albumin nanoparticle that is stable in the blood circulation but can release drugs into cells. Consequently, EeNA was fabricated by the nanoscale self-assembly of edaravone and albumin nanoparticles without the additives that are contained in commercially available edaravone preparations. EeNA retained its nanostructure under serum conditions, but the encapsulated edaravone was released efficiently under intracellular reducing conditions in macrophages. The EeNA was largely distributed in the liver and subsequently internalized into Kupffer cells within 60 min after injection in a concanavalin-A-induced hepatitis mouse. The survival rate of the hepatitis mice was significantly improved by EeNA due to the suppression of liver necrosis and oxidative stress by scavenging excessive ROS. Moreover, even through the postadministration, EeNA showed an excellent hepatoprotective action as well. In conclusion, EeNA has the potential for use as a nanotherapeutic against various types of hepatitis because of its Kupffer cell targeting ability and redox characteristics.
Collapse
Affiliation(s)
- Kengo Yasuda
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Hitoshi Maeda
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Ryo Kinoshita
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Yuki Minayoshi
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Yuki Mizuta
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Yuka Nakamura
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Shuhei Imoto
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
- DDS Research Institute, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| | - Koji Nishi
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| | - Keishi Yamasaki
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| | - Mina Sakuragi
- Faculty of Engineering, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| | - Teruya Nakamura
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Mayumi Ikeda-Imafuku
- School of Pharmaceutical Sciences, Wakayama Medical University, 25-1 Shichiban-Cho, Wakayama 640-8156, Japan
| | - Yasunori Iwao
- School of Pharmaceutical Sciences, Wakayama Medical University, 25-1 Shichiban-Cho, Wakayama 640-8156, Japan
| | - Yu Ishima
- Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan
| | - Tatsuhiro Ishida
- Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan
| | - Yasuko Iwakiri
- Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut 06510, United States
| | - Masaki Otagiri
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| | - Hiroshi Watanabe
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Toru Maruyama
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1, Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| |
Collapse
|
5
|
Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VTG, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T. Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models. J Pharmacol Exp Ther 2014; 352:244-57. [PMID: 25398242 DOI: 10.1124/jpet.114.219493] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Since reactive oxygen species (ROS) derived from Kupffer cells (KC), especially CD68(+) KC, play a key role in the induction of hepatic oxidative stress and injuries, we developed a polythiolated- and mannosylated human serum albumin (SH-Man-HSA), which functions as a novel nanoantioxidant for delivering thiol to CD68(+) KC. In vitro electron paramagnetic resonance coupled with pharmacokinetics and immunohistochemical studies showed that SH-Man-HSA possessed powerful radical-scavenging activity and rapidly and selectively delivered thiols to the liver via mannose receptor (CD206) on CD68(+) cells. SH-Man-HSA significantly improved the survival rate of concanavalin-A (Con-A)-treated mice. Moreover, SH-Man-HSA exhibited excellent hepatoprotective functions, not by decreasing tumor necrosis factor or interferon-γ production that is closely associated with Con-A-induced hepatitis, but by suppressing ROS production. Interestingly, the protective effect of SH-Man-HSA was superior to N-acetyl cysteine (NAC). This could be attributed to the difference in the inhibition of hepatic oxidative stress between the two antioxidants depending on their potential for thiol delivery to the liver. Similar results were also observed for acetaminophen (APAP)-induced hepatopathy models. Flow cytometric data further confirmed that an increase in F4/80(+)/ROS(+) cells was dramatically decreased by SH-Man-HSA. The administration of SH-Man-HSA at 4 hours following a Con-A or APAP injection also exhibited a profound hepatoprotective action against these hepatitis models, whereas this was not observed for NAC. It can be concluded therefore that SH-Man-HSA has great potential for use in a rescue therapy for hepatopathy as a nanoantioxidant because of its ability to efficiently and rapidly deliver thiols to CD68(+)/CD206(+) KC.
Collapse
Affiliation(s)
- Hitoshi Maeda
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Kenshiro Hirata
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Hiroshi Watanabe
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Yu Ishima
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Victor Tuan Giam Chuang
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Kazuaki Taguchi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Akihito Inatsu
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Manabu Kinoshita
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Motohiko Tanaka
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Yutaka Sasaki
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Masaki Otagiri
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| | - Toru Maruyama
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences (H.M., K.H., H.W., Y.I., V.T.G.C., T.M.), Center for Clinical Pharmaceutical Sciences, School of Pharmacy (H.W., Y.I., T.M.), and Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences (M.T., Y.S.), Kumamoto University, Kumamoto, Japan; School of Pharmacy, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia (V.T.G.C.); Faculty of Pharmaceutical Sciences (K.T., M.O.) and DDS Research Institute (M.O.), Sojo University, Kumamoto, Japan; and Department of Immunology and Microbiology, National Defense Medical College, Saitama, Japan (A.I., M.K.)
| |
Collapse
|